patient testing News
-
New Product Launch For EKF Diagnostics
EKF Diagnostics Holdings has launched its latest product as it looks to identify new opportunities. EKF Link is a digital connectivity service for the secure management of point-of-care (POC) analysers and associated data on one platform. It is designed to enable the real-time remote management of data, such as patient test results, quality control, calibration results, operator ...
By MediWales
-
Demo Presentations at Clinics
ExoAtlet team held a demo presentation in one of the European clinics recently. We had a huge success: more than 20 doctors gathered for the theoretical and practical part, which included doctors’ training and patients’ test drive of the ExoAtlet II exoskeleton. We are thankful to our large audience for the unwavering attention and support! We do appreciate the enthusiasm and ...
By ExoAtlet
-
Engaging Doctors and Nurses in process changes with the vital hub internet phone application
TOPIC: Engaging Doctors and Nurses in Process Changes with the Vital Hub Internet Phone Application Plenary Session 7 Healthcare Management Forum: Process Improvement and Operational Excellence WHEN: Tuesday, April 5 2011 at 9:00 a.m WHERE: Toronto Priority Code: 3BL1 Featuring: Neil Closner, Vice-President, Business Development, Mount Sinai Hospital Mount Sinai Hospital developed an in house ...
By 3BL Media
-
HiberGene Diagnostics introduces brand new UK division at NEQAS event
HiberGene Diagnostics, the leading manufacturer of molecular diagnostics products in Ireland, is pleased to announce that it will supply its innovative point-of-care (POC) and near-patient testing solutions directly to healthcare providers in the UK and Ireland. These high-quality testing solutions cover infectious and transmissible disease areas – including respiratory, sexually ...
-
Lumos Diagnostics Receives Authorization for CoviDx™ SARS-CoV-2 Rapid Antigen Test in Canada
Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that Health Canada has granted Interim Order authorization for the Lumos CoviDx™ SARS-CoV-2 Rapid Antigen Test. The CoviDx test gives qualified healthcare providers qualitative, easy-to-interpret results within 15-20 minutes in cases of suspected COVID-19 and when performing serial ...
-
Vantage is now a LFPSE Compliant Software Supplier!
Vantage is LFPSE Compliant! We are thrilled to announce that Vantage, has successfully passed NHS England’s rigorous LFPSE (Learning from Patient Safety Events) compliance testing and are officially recognised as an accredited LFPSE supplier. This accreditation is a testament to our commitment to enhancing patient safety in healthcare organisations across the nation. With the ...
-
THORASYS receives funding aimed at accelerating innovation
THORASYS is pleased to announce that it is receiving advisory services and up to $197,293 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development project in digital health. Thanks to this support, THORASYS will accelerate a strategic innovation aimed at assessing lung function in remote patient ...
-
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...
-
Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test. In written feedback to the ...
-
Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing ...
-
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced completion of its previously planned clinical studies for the Symphony IL-6 Test (the “Test”). Results of these studies will be ...
-
Notal Vision Monitoring Center Reports AI Analysis of 10 Million ForeseeHome AMD Home Monitoring Tests
Manassas, Virginia (November 30, 2021) - The Notal Vision Monitoring Center celebrates the artificial intelligence (Al) based analysis of the ten millionth test performed by over 20,000 patients with the FDA-cleared ForeseeHome device. The device is part of a comprehensive remote monitoring service for intermediate age-related macular degeneration (AMD) patients at risk of developing the sight ...
-
Seventh Sense Biosystems Expands to European Markets for Consumer Blood Collection with TAP II CE Marking
Seventh Sense Biosystems, Inc. (7SBio), developers of the world’s first push-button blood collection device, announced today that the company has received CE mark approval from the European Commission for its TAP® II blood collection device. This clearance opens up European Union markets for consumers and patients to access simple, convenient, and more comfortable blood collection ...
-
CardioWise Receives Supplemental Grant from the National Science Foundation
CardioWise, Inc. has received a National Science Foundation (NSF) Phase IB Small Business Innovation Research grant of $30,000 to continue the development and commercialization of a non-invasive analysis method for detection of heart disease. This award follows and builds on the successful achievement of milestones in a Phase I grant of $150,000 received by the company in January. The Phase IB ...
-
Quadrant Biosciences Receives Breakthrough Device Designation for Novel Autism Saliva Test
Quadrant Biosciences Inc., a developer of novel molecular diagnostic tools, has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its innovative Clarifi ASD® autism saliva test. Clarifi ASD is indicated for use in assessing the likelihood that a child has autism spectrum disorder (ASD) based on ...
-
VUNO Med-DeepECG Designated as Breakthrough Device
South Korean artificial intelligence (AI) developer, VUNO inc. announced that the Korean Ministry of Food and Drug Safety (KFDA) has designated the company’s artificial intelligence-based electrocardiogram (ECG) analysis software VUNO Med®-DeepECG™ as the ministry’s 16th Breakthrough Device. Using deep learning, the software analyzes ECG data to zero in on heart failure, ...
By Vuno Inc.
-
SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer
SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS® Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS® Test (abstract number 534) at the American Association for Cancer Research annual ...
-
Spotlight from Canada Economic Development on Puzzle Medical`s journey
The idea of developing a minimally invasive heart pump arose during an entrepreneurship course at the École de technologie supérieure (ÉTS) being taken in 2018 by two mechanical engineering and robotics students, Jade Doucet-Martineau and François Trudeau, and during a discussion on the subject with a colleague, Dr. Gabriel Georges. Together, they observed that current ...
-
Digital Diagnostics and Orbis International announce study to help save sight in Bangladesh
(Coralville, IA.) May 19, 2021 – Digital Diagnostics, developers of IDx-DR, an FDA De Novo-cleared autonomous AI system for the detection of diabetic retinopathy (DR) and diabetic macular edema (DME), and Orbis International, the influential nonprofit dedicated to fighting avoidable blindness around the world, have partnered on a study that will bring high-quality disease detection to ...
-
Beckman Coulter Introduces Antipsychotic Drug Testing to Address Unmet Clinical Need for More Than 69 Million People Living with Serious Mental Conditions
Beckman Coulter, a global clinical diagnostics leader, announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests designed to measure blood levels of antipsychotic drugs ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you